Literature DB >> 25025274

Liver cell-targeted delivery of therapeutic molecules.

Jeong-Hun Kang1, Riki Toita2, Masaharu Murata3,4.   

Abstract

The liver is the largest internal organ in mammals and is involved in metabolism, detoxification, synthesis of proteins and lipids, secretion of cytokines and growth factors and immune/inflammatory responses. Hepatitis, alcoholic or non-alcoholic liver disease, hepatocellular carcinoma, hepatic veno-occlusive disease, and liver fibrosis and cirrhosis are the most common liver diseases. Safe and efficient delivery of therapeutic molecules (drugs, genes or proteins) into the liver is very important to increase the clinical efficacy of these molecules and to reduce their side effects in other organs. Several liver cell-targeted delivery systems have been developed and tested in vivo or ex vivo/in vitro. In this review, we discuss the literature concerning liver cell-targeted delivery systems, with a particular emphasis on the results of in vivo studies.

Entities:  

Keywords:  Drug delivery; endocytosis; gene delivery; hepetocyte; nanoparticle; polymer; viral vector

Mesh:

Substances:

Year:  2015        PMID: 25025274     DOI: 10.3109/07388551.2014.930017

Source DB:  PubMed          Journal:  Crit Rev Biotechnol        ISSN: 0738-8551            Impact factor:   8.429


  10 in total

Review 1.  Applications of human hepatitis B virus preS domain in bio- and nanotechnology.

Authors:  Riki Toita; Takahito Kawano; Jeong-Hun Kang; Masaharu Murata
Journal:  World J Gastroenterol       Date:  2015-06-28       Impact factor: 5.742

2.  Cell-specific expression of the analgesic-antitumor peptide coding sequence under the control of the human α-fetoprotein gene promoter and enhancer.

Authors:  Sisi Jin; Xianfan Lin; Huaqin Guan; Jinming Wu
Journal:  Exp Ther Med       Date:  2015-01-02       Impact factor: 2.447

3.  Asialoglycoprotein receptor-magnetic dual targeting nanoparticles for delivery of RASSF1A to hepatocellular carcinoma.

Authors:  Wan-Jiang Xue; Ying Feng; Fei Wang; Yi-Bing Guo; Peng Li; Lei Wang; Yi-Fei Liu; Zhi-Wei Wang; Yu-Min Yang; Qin-Sheng Mao
Journal:  Sci Rep       Date:  2016-02-26       Impact factor: 4.379

4.  Size-dependent cytotoxicity of Fe3O4 nanoparticles induced by biphasic regulation of oxidative stress in different human hepatoma cells.

Authors:  Yuexia Xie; Dejun Liu; Chenlei Cai; Xiaojing Chen; Yan Zhou; Liangliang Wu; Yongwei Sun; Huili Dai; Xianming Kong; Peifeng Liu
Journal:  Int J Nanomedicine       Date:  2016-07-29

5.  Nano-sized cytochrome P450 3A4 inhibitors to block hepatic metabolism of docetaxel.

Authors:  Marion Paolini; Laurence Poul; Céline Berjaud; Matthieu Germain; Audrey Darmon; Maxime Bergère; Agnès Pottier; Laurent Levy; Eric Vibert
Journal:  Int J Nanomedicine       Date:  2017-08-02

6.  Interference with KCTD9 inhibits NK cell activation and ameliorates fulminant liver failure in mice.

Authors:  Xiaoping Zhang; Lin Zhu; Yaoyong Zhou; Aichao Shi; Hongwu Wang; Meifang Han; Xiaoyang Wan; Semvua Bukheti Kilonzo; Xiaoping Luo; Tao Chen; Qin Ning
Journal:  BMC Immunol       Date:  2018-06-25       Impact factor: 3.615

Review 7.  Drug delivery strategy in hepatocellular carcinoma therapy.

Authors:  Sisi Yang; Chengwei Cai; Huanqiu Wang; Xueqing Ma; Anwen Shao; Jifang Sheng; Chengbo Yu
Journal:  Cell Commun Signal       Date:  2022-03-05       Impact factor: 5.712

Review 8.  Liver-specific drug delivery platforms: Applications for the treatment of alcohol-associated liver disease.

Authors:  Jeffrey Barr Warner; Steven Corrigan Guenthner; Josiah Everett Hardesty; Craig James McClain; Dennis Ray Warner; Irina Andreyevna Kirpich
Journal:  World J Gastroenterol       Date:  2022-09-28       Impact factor: 5.374

Review 9.  Liver Cancer: Current and Future Trends Using Biomaterials.

Authors:  Sue Anne Chew; Stefania Moscato; Sachin George; Bahareh Azimi; Serena Danti
Journal:  Cancers (Basel)       Date:  2019-12-16       Impact factor: 6.639

Review 10.  Endothelial dysfunction in pathological processes of chronic liver disease during aging.

Authors:  Ying Wan; Xuedong Li; Elise Slevin; Kelly Harrison; Tian Li; Yudian Zhang; James E Klaunig; Chaodong Wu; Ashok K Shetty; X Charlie Dong; Fanyin Meng
Journal:  FASEB J       Date:  2022-01       Impact factor: 5.834

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.